Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record, with a small difference in title or year; 39 of the 39 references it cites were found in a registry or an index; 5 of the 14 sources its claims cite were checked for support.

Managing Cancer And Living Meaningfully (CALM): randomised feasibility trial in patients with advanced cancer

Open access

Abstract

Background Managing Cancer And Living Meaningfully (CALM) is a brief individual psychotherapy for patients with advanced cancer. In an intervention-only phase 2a trial, CALM showed promising results, leading to the present 2b pilot, which introduces procedures for randomisation and improved rigour in preparation for a phase 3 randomised controlled trial (RCT). Aims To test trial methodology and assess feasibility of a confirmatory RCT. Design A parallel-arm RCT (intervention vs usual care) with 3 and 6-month follow-ups. Assessment of feasibility included rates of consent, randomisation, attrition, intervention non-compliance and usual care contamination. Primary outcome: Depressive symptoms (Patient Health Questionnaire-9; PHQ-9). Secondary outcomes: Major depressive disorder (MDD), generalised anxiety, death anxiety, spiritual well-being, attachment anxiety and avoidance, self-esteem, experiential avoidance, quality of life and post-traumatic growth. Bayesian conjugate analysis was used in this lowpowered setting. Setting/participants 60 adult patients with advanced cancer from the Princess Margaret Cancer Centre. Results Rate of consent was 32%, randomisation 78%, attrition 25%, noncompliance 37% and contamination 17%. There was support for potential treatment effects on: PHQ-9, OR=1.48, 95% Credible Interval (CRI.95) (0.65, 3.38); MDD, OR=1.56, CRI.95 (0.50, 4.84); attachment anxiety, OR=1.72, CRI.95 (0.73, 4.03); and attachment avoidance, OR=1.58, CRI.95 (0.67, 3.71). There was no support for effects on the seven remaining secondary outcomes. Conclusions A phase 3 CALM RCT is feasible and should aim to detect effect sizes of d=0.40, with greater attention to issues of compliance and contamination. © 2019 Author(s).

Overview

CoChat Summary

TL;DR

This phase 2b randomized feasibility trial found that a phase 3 CALM trial in advanced cancer patients is feasible, with 32% consent, 78% randomization, 25% attrition, 37% intervention non-compliance, and 17% contamination of usual care. The study was not powered for efficacy, but it showed possible benefit for depressive symptoms and attachment outcomes, with the authors recommending a future trial powered to detect effect sizes of d = 0.40.

Key findings

  • Recruitment/feasibility metrics: 75% (237/316) of screened individuals were eligible, 32% (77/237) consented, 78% (60/77) were randomized, 25% (15/60) were lost to attrition by study end, 37% (11/30) of CALM participants were non-compliant (<3 sessions), and 17% (5/30) of usual care participants had contamination.
  • Primary outcome (PHQ-9): the posterior mean odds ratio for improvement was 1.48, with a 95% credible interval of 0.65 to 3.38, and a 66% probability of OR > 1.25.
  • Secondary outcomes: there was support for effects on MDD diagnosis (OR 1.56, 95% credible interval 0.50 to 4.84; 65% probability of OR > 1.25), attachment anxiety (OR 1.72, 0.73 to 4.03; 76% probability), and attachment avoidance (OR 1.58, 0.67 to 3.71; 71% probability).
  • No support was found for the other 7 secondary outcomes; their probabilities of OR > 1.25 ranged from 8% to 34%.

Methods

  • Parallel-arm randomized controlled pilot trial (phase 2b) comparing CALM vs usual care, with assessments at baseline, 3 months, and 6 months.
  • Sample: 60 adult outpatients with advanced or metastatic cancer from the Princess Margaret Cancer Centre in Toronto; eligibility required English fluency and specific advanced cancer diagnoses, and excluded cognitive impairment or active inpatient psychiatric/psychological treatment.
  • Main analysis: feasibility was assessed via consent, randomization, attrition, non-compliance, and contamination; outcomes were analyzed with Bayesian conjugate analyses focusing on the 6-month endpoint, using improvement thresholds roughly corresponding to effect sizes of d = 0.40.

Limitations

  • The paper states the study was not powered to confirm treatment efficacy and that caution is warranted in interpreting effects.
  • The study was limited by small sample size and representativeness: most participants were married, well-educated, English-speaking, Caucasian, and female with advanced gastrointestinal cancer.
  • The study was unblinded, which may have affected outcomes, and participants were not selected for elevated distress, which may have limited detectable benefit.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmjspcare-2015-000866

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
From the PDF

Verification

Claims the paper makes

5 Valid · 3 Not valid · 4 Not checked · 48 Own results and interpretations

21 more claims

Create a free account to see all 60 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 20

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 39 references

Research works printed but not linked: 1

  1. First MB , Spitzer RL , Gibbon M , et al . Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Patient Edition (SCID-I/P, 1/2010 revision). New York, NY: New York State Psychiatric Institute, 2010.

Cited by

See all 87

Metadata

Authors
Lo, C., Hales, S., Chiu, A., Panday, T., Malfitano, C., Jung, J., Rydall, A., Li, M., Nissim, R., Zimmermann, C., & Rodin, G.
Affiliations
University Health Network (CA)
Corresponding author
Rodin, Gary
Venue
BMJ Supportive & Palliative Care
Publisher
BMJ
Published
2016-01-19
Volume
9
Issue
2
Pages
209-218
ISSN
  • 2045-435X (ISSN-L)
  • 2045-4368
OpenAlex
W2299951753
Cited by
87
References
39
Citations by year
2026: 4 · 2025: 10 · 2024: 8 · 2023: 6 · 2022: 9 · 2021: 4 · 2020: 9 · 2019: 10 · 2018: 11 · 2017: 13 · 2016: 3
FWCI
6.64
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • BMJ Supportive & Palliative Care (publishedVersion)
  • PubMed (publishedVersion)
  • ResearchOnline at James Cook University (James Cook University) (submittedVersion)
  • TSpace (University of Toronto) (submittedVersion, cc-by-nc-nd)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Cancer Research Institute
  • Princess Margaret Cancer Foundation
  • University of Toronto
  • Canadian Institutes of Health Research (MOP106473)
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative and Oncologic Care
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative Care and End-of-Life Issues
Keywords
CALM, advanced cancer, feasibility trial, depressive symptoms, major depressive disorder, attachment anxiety, attachment avoidance, spiritual well-being, quality of life, posttraumatic growth, intervention adherence, attrition
MeSH terms
Adaptation, Psychological, Adult, Aged, Bayes Theorem, Cost-Benefit Analysis, Female, Humans, Male, Middle Aged, Neoplasms, Ontario, Pilot Projects, Psychotherapy, Brief, Quality of Life, Stress, Psychological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Managing Cancer And Living Meaningfully (CALM): randomised feasibility trial in patients with advanced cancer. https://app.cochat.ai/papers/10.1136/bmjspcare-2015-000866
The paper
Lo, C., Hales, S., Chiu, A., Panday, T., Malfitano, C., Jung, J., Rydall, A., Li, M., Nissim, R., Zimmermann, C., & Rodin, G. (2019). Managing Cancer And Living Meaningfully (CALM): randomised feasibility trial in patients with advanced cancer. BMJ Supportive & Palliative Care. https://doi.org/10.1136/bmjspcare-2015-000866

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.